Description
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.In VitroGLP-1(32-36)amide (0.1-10 µM; 24 h) retains cell viability and decreases apoptosis against Streptozotocin (STZ; 1 µM) in INS-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: INS-1 cells Concentration: 0.1, 1, 10 µM Incubation Time: 24 hours Result: Decreased cell viability only approximately 30% in 0.1 µM and approximately 20% in ≥1 µM while approximately 45% in saline-treated controls.In VivoGLP-1(32-36)amide (1 µmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice. GLP-1(32-36)amide (1 µmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice. GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male KM mice (6-8 weeks; 18-22 g) injected with STZDosage: 1 µmol/kg Administration: I.p. once daily for 21 days Result: Significantly lowered the cumulative values of food and water intake. Lowered fasting glucose. Reduced the level of Hemoglobin A1c (HbA1c). Improved glucose tolerance. Suppressed body weight gain.Form:Solid